MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) announced today that it has filed a prior approval supplement with the U.S. Food and Drug Administration (FDA) seeking approval to market in the United States 1000 mg strength tablets of GlumetzaTM(metformin hydrochloride extended release tablets). The company expects the FDA to make a determination on the filing before the end of the third quarter of this year.
